AERI - Aerie Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
46.82
-2.43 (-4.93%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close49.25
Open48.72
Bid36.32 x 900
Ask47.10 x 800
Day's Range45.79 - 49.40
52 Week Range32.18 - 74.75
Volume620,874
Avg. Volume679,826
Market Cap2.15B
Beta (3Y Monthly)0.45
PE Ratio (TTM)N/A
EPS (TTM)-5.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est79.90
Trade prices are not sourced from all markets
  • Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan
    Zacks2 days ago

    Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan

    Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.

  • Business Wire3 days ago

    Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa® in the United States and is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  • Business Wire6 days ago

    Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in a Phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This Phase 2 study (AR1105-CS201) will be conducted at approximately 20 centers in the United States and enroll up to 45 patients. In the initial safety stage, up to 5 patients will be enrolled in a single cohort to receive clinical formulation #1 (CF-1), delivering a 340µg dose of dexamethasone in a single intravitreal injection.

  • Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma
    Zacks11 days ago

    Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma

    Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.

  • Benzinga11 days ago

    The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...

  • Business Wire12 days ago

    Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced full-year 2019 net revenue and net cash burn guidance. With the recently announced FDA approval of RocklatanTM (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the Company announced full-year 2019 net revenue guidance in the range of $110 million to $120 million. This guidance includes the combined net revenues for Rhopressa® (netarsudil ophthalmic solution) 0.02% and RocklatanTM.

  • Business Wire12 days ago

    Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. A link to the full product label is available on the Aerie website at http://investors.aeriepharma.com.

  • Introducing Aerie Pharmaceuticals, The Stock That Zoomed 271% In The Last Three Years
    Simply Wall St.17 days ago

    Introducing Aerie Pharmaceuticals, The Stock That Zoomed 271% In The Last Three Years

    It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But when you pick aRead More...

  • Markit19 days ago

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Aerie Pharmaceuticals Inc NASDAQ NMS:AERIView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 12. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding AERI totaled $97 million. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire19 days ago

    Aerie Pharmaceuticals to Present at Two Investor Conferences in March

    Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present an Aerie overview and provide a business update ...

  • GlobeNewswire23 days ago

    New Research Coverage Highlights Micron Technology, Varian Medical, St. Joe, Himax Technologies, Aerie Pharmaceuticals, and Hexcel — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Thomson Reuters StreetEvents23 days ago

    Edited Transcript of AERI earnings conference call or presentation 25-Feb-19 10:00pm GMT

    Q4 2018 Aerie Pharmaceuticals Inc Earnings Call

  • Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction
    Zacks26 days ago

    Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction

    Aerie (AERI) reports wider-than-expected Q4 loss. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

  • Aerie Pharmaceuticals Inc (AERI) Q4 2018 Earnings Conference Call Transcript
    Motley Fool27 days ago

    Aerie Pharmaceuticals Inc (AERI) Q4 2018 Earnings Conference Call Transcript

    AERI earnings call for the period ending December 31, 2018.

  • Business Wire27 days ago

    Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update

    Conference Call and Webcast Today, February 25th, at 5:00 p.m. ET

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

    Biotech stocks came under pressure in the week ending Feb. 22 after advancing in the previous week. The recent week was fairly quiet for the space, with a few earnings reports from small-cap stocks and ...

  • Business Wirelast month

    Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its fourth quarter and full year 2018 financial results will be released after the market closes on Monday, February 25, 2019. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results, provide 2019 cash burn guidance and a general business update. The live webcast and a replay may be accessed by visiting the Company’s website at http://investors.aeriepharma.com.

  • Mizuho's 9 Best Biotech Stocks to Buy for 2019
    Kiplinger2 months ago

    Mizuho's 9 Best Biotech Stocks to Buy for 2019

    Biotech stocks are a staple among growth investors. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the risk is just as high. It's not unusual for these stocks to be cut in half or worse if drug-trial data disappoints or a drug application is rejected. Thus, proper due diligence is critical, and that includes tapping the experts for information about these often difficult-to-gauge stocks. Mizuho Securities has recently put out an analyst report highlighting its top biotechnology picks for 2019. And thanks to analyst ranking service TipRanks, we can see that the report's author, Managing Director Difei Yang, has a strong track record of stock recommendations. Yang is ranked in the top 250 out of more than 5,100 tracked analysts. Yang writes, "We favor innovative and ground-breaking therapies in 2019; emerging technologies such as gene therapy and cell therapy could command substantial premiums from large cap pharma/biotech if impressive results are shown in historically difficult-to-treat conditions." As Yang points out, pharma M&A; is off to a strong start in 2019 with a number of blockbuster deals. They include Bristol-Myers Squibb's (BMY) $74 billion acquisition of Celgene (CELG), and Eli Lilly's (LLY) $8 billion buyout of Loxo Oncology (LOXO). "In our view, the transactions underscore the persistent need by large pharma to fuel continued growth and replenish R&D; pipelines via M&A;," she writes. Here are Mizuho's top nine biotech stocks to buy right now. Many of them can stand on their own but look even better as potential buyout targets. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)

  • Aerie Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?
    Zacks2 months ago

    Aerie Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?

    Aerie Pharmaceuticals has moved higher as of late, but there could definitely be trouble on the horizon for this company.

  • Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
    Zacks2 months ago

    Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies

    Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA. The candidate will now enter clinical studies.

  • A Spotlight On Aerie Pharmaceuticals, Inc.’s (NASDAQ:AERI) Fundamentals
    Simply Wall St.2 months ago

    A Spotlight On Aerie Pharmaceuticals, Inc.’s (NASDAQ:AERI) Fundamentals

    I've been keeping an eye on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) because I'm attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe Read More...

  • Business Wire2 months ago

    Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 (Dexamethasone Intravitreal Implant)

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye today announced that the U.S. Food and Drug Administration (FDA) has reviewed the Investigational New Drug Application (IND) for AR-1105 (dexamethasone intravitreal implant) and it is now in effect, allowing Aerie to initiate human studies in the treatment of macular edema due to retinal vein occlusion (RVO). The IND was submitted in December 2018.